SGLT2 Inhibitors and Renal Anemia in Japan: RWD

The objectives of the study are: 1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control design with incidence density sampling. 2. To evaluate anemia-related outcomes using a nested case-control-based analytical framework, including assessment of within-subject changes in anemia-related treatments and healthcare costs by comparing the period after study entry with the period after the index date (for cases) or matched reference date (for controls), and comparison according to SGLT2 inhibitor use: A) Prescription patterns and treatment regimens for anemia, including analysis of medication types, dosing strategies, and duration of treatments B) Anemia-related healthcare costs C) Change in laboratory values

NCT Number	NCT07063316
Lead Sponsor	Boehringer Ingelheim Collaborators: Eli Lilly and Company
Conditions	Chronic Kidney Disease
Enrollment	15,000 participants
Start Date	2025-07-23
Primary Completion	2026-12-25 (estimated)
Study Completion	2026-12-25 (estimated)
Updated on ClinicalTrials.gov	2026-05-08